vinyl]-A2-1,2,4-oxadiazole (SQ 18,506), originally synthesized by Breuer (2) , possesses potent activity in vitro against gram-positive and gram-negative bacteria, certain fungi, and Trichomonas vaginalis (4) . More recently, the compound has shown marked chemotherapeutic activity in animals infected with Schistosoma mansoni (3), Schistosoma japonicum (3) , and some degree of activity against Escherichia coli, Candida albicans, or Trichomonas foetus (5) .
The present study extends the evaluation in vitro of this nitrofuran.
MATERIALS AND METHODS Antimicrobial agents. Antimicrobial agents were supplied by Eaton Laboratories (furazolidone, lot no. 1814), Eli Lilly (penicillin V, 880 pg/mg) and Squibb (SQ 18,506, batch 11, average particle size 3 to 5 im).
Antimicrobial activity. Most of the cultures used in this study were recent clinical isolates of human origin. Minimal inhibitory concentrations (MIC) of SQ 18,506 against the isolates were determined by the conventional twofold dilution method with broth or agar; the growth media and test procedures used were previously described in detail (1, 6) . Minimal microbicidal concentrations (MMC) were determined by subculturing all tubes that showed no visible growth in a broth-dilution test onto antibiotic-free agar media. The MMC was defined as the lowest concentration of drug that gave no visible colonial growth on subculture after 48 h at 37 C. In experiments to determine the effect of serum on the antimicrobial activity of SQ 18,506, MIC determinations were made in the presence and absence of pooled human serum (BBL). SQ 18,506 and furazolidone were solubilized in dimethyl sulfoxide, and dilutions were prepared as needed in distilled water before the assessment of antimicrobial activity.
Stability in solution. SQ 18,506, solubilized in dimethyl sulfoxide, and penicillin V were prepared in 0.05 M phosphate buffer (pH values 2.0 to 8.0) at a concentration of 1 mg/ml and held at 37 C for 24 h. At 4 and 24 h, 0.03-ml samples of the test solutions were assayed for bioactivity by using a disk diffusion assay on plates seeded with Staphylococcus aureus P-209 (1). Zones of inhibition were measured after 18 h of incubation at 37 C, and the residual activity was determined. Resistance development. A twofold broth-dilution test was used to ascertain the development of resistance to SQ 18,506 in vitro. After incubation for 18 h at 37 C, organisms from tubes containing the highest concentration of SQ 18,506 showing visible growth were used to inoculate the next series of tubes. The index of induced resistance was calculated at intervals, and after the final (twentieth) passage, by comparing the initial MIC of a culture to that obtained after various numbers of exposures to SQ 18,506.
Determination of median lethal dose. Experimental infections were produced in mice by the intraperitoneal injection of suitably diluted cultures. At least three different dose groups of the test organisms were used in twofold increments; each dose group consisted of ten animals. All mice were observed for fixed periods of time (Candida-infected, 30 to 60 h; bacteria-infected, 5 to 22 h; Trichomonasinfected, 7 to 14 days), and the median lethal dose was determined by the method of Reed and Muench (7).
RESULTS AND DISCUSSION Physical and chemical properties. SQ 18,506 (Fig. 1) is a light-yellow crystalline powder that is soluble in cold dimethyl sulfoxide or hot dimethylformamide at approximately 10% (wt/vol). It is virtually insoluble in water and lower alcohols, acetone, chloroform, ether, and benzene. Because of the low water solubility of the compound, SQ 18,506 was first solubilized in dimethyl sulfoxide before being used in studies to define its biological activity in vitro. Dilute solutions of SQ 18,506, when exposed to light, undergo rapid decomposition; concentrated solutions (about 25 mg or more per ml), allowed to stand for several days, showed less than 5% decomposition. Particle size varies from batch to batch, but can be adjusted rather easily to an average diameter of 3 to 5 gsm.
When solutions of SQ 18,506 were prepared in 0.05 M phosphate buffer, pH values 2.0 and 8.0, and held at 37 C for 24 h, both SQ 18,506 and a penicillin V control showed less than 5% loss in bioactivity over the entire pH range studied. The antimicrobial activity in vitro of SQ 18,506 was not significantly diminished by the addition of 50% human serum to the medium, nor was that of furazolidone, a marketed nitrofuran (Table 1) .
Antimicrobial activity. The exceedingly broad spectrum of SQ 18,506 was confirmed and extended to include a wide variety of bacteria and fungi. In all, 37 (77%) of 48 important disease-producing microorganisms were susceptible to the compound at an MIC of 10 ,g/ml or VOL. 6, 1974 cline, gentamicin, neomycin, kanamycin, chloramphenicol, nitrofurantoin, or sulfamethoxazole, as shown by its effectiveness against organisms resistant to these antimicrobial agents (Table 2 and 5). Some cross-resistance to furazolidone was shown.
